SELPLG and acute myeloid leukemia: In recipients of Selplg–/–AML BM, cytarabine treatment extended median survival by a further 30% (9.5 days) when compared to matched vehicle treated control mice, or 55% (17 days) when compared to saline-treated recipients of WT AML.